Compounds > caffeine

caffeine and esmolol

caffeine has been researched along with esmolol in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's4 (50.00)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Fligner, DJ; Price, KR1
Ramoska, EA; Richards, JR; Sand, IC1
Chevillard, L; Grémain, V; Mégarbane, B; Saussereau, E; Schnell, G1

Reviews

1 review(s) available for caffeine and esmolol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

7 other study(ies) available for caffeine and esmolol

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution

2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Treatment of caffeine toxicity with esmolol.
    Annals of emergency medicine, 1990, Volume: 19, Issue:1

    Topics: Adrenergic beta-Antagonists; Caffeine; Cardiac Complexes, Premature; Female; Humans; Infusions, Intravenous; Middle Aged; Propanolamines; Suicide, Attempted; Tachycardia, Supraventricular

1990
Beta-blocker treatment of caffeine-induced tachydysrhythmias.
    Clinical toxicology (Philadelphia, Pa.), 2016, Volume: 54, Issue:5

    Topics: Adrenergic beta-Antagonists; Caffeine; Catecholamines; Humans; Propanolamines; Tachycardia, Ventricular; Vasoconstriction

2016
Massive suicidal ingestion of caffeine: a case report with investigation of the cardiovascular effect/concentration relationships.
    Clinical toxicology (Philadelphia, Pa.), 2021, Volume: 59, Issue:10

    Topics: Administration, Oral; Adrenergic alpha-Agonists; Adrenergic beta-1 Receptor Antagonists; Caffeine; Cardiotoxicity; Central Nervous System Stimulants; Electric Countershock; Half-Life; Heart Rate; Humans; Hyperlactatemia; Infusions, Intravenous; Intubation, Intratracheal; Male; Metabolic Clearance Rate; Middle Aged; Norepinephrine; Powders; Propanolamines; Suicide, Attempted; Tachycardia; Treatment Outcome; Ventricular Fibrillation

2021